Sobi’s Pozdeutinurad Lowers Urate Levels in Phase 3 Gout Trial
Sobi said its Phase 3 trial found that pozdeutinurad reduced urate levels in patients with gout.
Related stories
Regal Rexnord Reports Q3 Revenue of $1.59B
Regal Rexnord reported Q3 revenue of $1.59 billion, versus a FactSet estimate of $1.56 billion.
M impact | EQUITY | Nov 03, 2026, 12:16 PM UTC
Precision BioSciences Reports Q3 Loss
Precision BioSciences reported a loss for the third quarter.
M impact | EQUITY | Nov 03, 2026, 12:12 PM UTC
Versant Q3 2026 net profit falls; revenue also declines
M impact | EQUITY | Nov 03, 2026, 12:12 PM UTC
Keurig Dr Pepper Shares Rise About 1% Premarket After Q3 Results Beat Estimates
M impact | EQUITY | Nov 03, 2026, 12:12 PM UTC
Teva Q3 revenue falls 2% as generics decline
Teva reported a 2% decline in Q3 revenue as generics declined.
M impact | EQUITY | Nov 03, 2026, 12:12 PM UTC
Arvinas Q3 Net Loss Widens 54% to $53.9 Million as Revenue Falls 99%
Arvinas reported a third-quarter net loss of $53.9 million, up 54%, while revenue fell 99% to $500,000.
M impact | EQUITY | Nov 03, 2026, 12:11 PM UTC